Cited by 186Diabetes Management and ResearchDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Insulin glargine

Bolli, Geremia B, Owens, David R·2000·The Lancet

DOI 10.1016/s0140-6736(00)02546-0

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(00)02546-0

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739
Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.
Pickup, J. C., KEEN, H., PARSONS, J. A., & Alberti, K. G. M. M. (1978) · BMJ · doi:10.1136/bmj.1.6107.204 · Cited by 563
Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor
Smith, L. E. H., Shen, W., Perruzzi, C. A., Söker, S., Kinose, F., Xu, X., Robinson, G. S., Driver, S., Bischoff, J. E., Zhang, B., et al. (1999) · Nature Medicine · doi:10.1038/70963 · Cited by 555
Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
Heinemann, L., Linkeschova, R., Rave, K., Hompesch, B., Sedlak, M., & Heise, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.644 · Cited by 474
Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes
Ratner, R. E., Hirsch, I. B., Neifing, J. L., Garg, S. K., Mecca, T. E., & Wilson, C. A. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.639 · Cited by 455
Insulin analogues and their potential in the management of diabetes mellitus
Bolli, G. B., DiMarchi, R. D., Park, G. D., Pramming, S., & Koivisto, V. A. (1999) · Diabetologia · doi:10.1007/s001250051286 · Cited by 351
Self-citation
Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens
Jehle, P. M., Micheler, C., Jehle, D. R., Breitig, D., & Boehm, B. O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12459-5 · Cited by 185
Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor
Slieker, L. J., Brooke, G. S., DiMarchi, R. D., Flora, D. B., Green, L. K., Hoffmann, J. A., Long, H. B., Fan, L., Shields, J. E., Sundell, K. L., et al. (1997) · Diabetologia · doi:10.1007/s001250051402 · Cited by 138
The Long Acting Human Insulin Analog HOE 901: Characteristics of Insulin Signalling in Comparison to Asp(B10) and Regular Insulin
Berti, L., Kellerer, M., Bossenmaier, B., Seffer, E., Seipke, G., & Häring, H.-U. (1998) · Hormone and Metabolic Research · doi:10.1055/s-2007-978849 · Cited by 93
Diabetes: Current Perspectives
Betteridge, D. J. (1999) · Cited by 22

Show all 10 references

Research works printed but not linked: 4

Lepore, 1999, Pharmacokinetics and dynamics of s. c. injection of the long-acting insulin glargine (HOE901) in T1DM, Diabetes, 48, A97
Pieber, 1999, Efficacy and safety of HOE 901 in patients with type 1 diabetes: a four-week randomised, NPH insulin-controlled trial, Diabetes, 47, A62
Yki-Järvinen, 2000, Study Group – HOE 901/3002. Comparison of insulin glargine (HOE901) vs NPH during 1 year of insulin combination therapy in Type 2 diabetes, Diabetes, 49, A130
Bolli, 1999, Rationale for using combinations of short-acting insulin analogue and NPH insulins at mealtime in the treatment of Type 1 diabetes mellitus, J Ped Endocrinol Metab, 12, 737

Sorted by citations

Type 1 diabetes: new perspectives on disease pathogenesis and treatment
Atkinson, M. A., & Eisenbarth, G. S. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05415-0 · Cited by 1,491
Untitled work
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
Brown, R. J., Araújo‐Vilar, D., Cheung, P. T., Dunger, D. B., Garg, A., Jack, M., Mungai, L., Oral, E. A., Patni, N., Rother, K. I., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2466 · Cited by 540
ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus
(2018) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002960 · Cited by 488
The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin
Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J., & Kurtzhals, P. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000036926.54824.37 · Cited by 431
Type 1 diabetes: recent developments
Devendra, D., Liu, E., & Eisenbarth, G. S. (2004) · BMJ · doi:10.1136/bmj.328.7442.750 · Cited by 362
Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies
Heise, T., & Pieber, T. R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00756.x · Cited by 236
Insulin structure and function
Mayer, J. P., Zhang, F. P. Y., & DiMarchi, R. D. (2007) · Biopolymers · doi:10.1002/bip.20734 · Cited by 248
Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs
Vajó, Z., Fawcett, J., & Duckworth, W. C. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.5.0442 · Cited by 179
A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes
Hollander, P. A., Cooper, J., Bregnhøj, J. F., & Pedersen, C. B. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.001 · Cited by 161
Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews
Martis, R., Crowther, C. A., Shepherd, E., Alsweiler, J., Downie, M. R., & Brown, J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012327.pub2 · Cited by 159
Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy
Owen, A., & Rannard, S. P. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.003 · Cited by 161
Intensive Replacement of Basal Insulin in Patients With Type 1 Diabetes Given Rapid-Acting Insulin Analog at Mealtime
Rossetti, P., Pampanelli, S., Fanelli, C. G., Porcellati, F., Costa, E., Torlone, E., Scionti, L., & Bolli, G. B. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1490 · Cited by 152
Self-citation
Insulin glargine: A systematic review of a long-acting insulin analogue
Wang, F., Carabino, J. M., & Vergara, C. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80156-x · Cited by 143
Insulin detemir: from concept to clinical experience
Home, P., & Kurtzhals, P. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.3.325 · Cited by 139
Perimacular retinal folds from childhood head trauma
Lantz, P., Sinal, S. H., Stanton, C. A., & Weaver, R. G. (2004) · BMJ · doi:10.1136/bmj.328.7442.754 · Cited by 131
Long-Acting Insulin Analogs Versus Insulin Pump Therapy for the Treatment of Type 1 and Type 2 Diabetes
Pickup, J. C., & Renard, É. (2008) · Diabetes Care · doi:10.2337/dc08-s235 · Cited by 107
Basal insulin analogues in the management of diabetes mellitus: what progress have we made?
Owens, D. R., Matfin, G., & Monnier, L. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2469 · Cited by 102
Self-citation
Insulin Glargine
Dunn, C. J., Plosker, G. L., Keating, G. M., McKeage, K., & Scott, L. J. (2003) · Drugs · doi:10.2165/00003495-200363160-00007 · Cited by 95
Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial
Heller, S. R., Koenen, C., & Bode, B. W. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.10.006 · Cited by 94
Refining basal insulin therapy: what have we learned in the age of analogues?
DeVries, J. H., Nattrass, M., & Pieber, T. R. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.762 · Cited by 94
Evolution of Insulin: From Human to Analog
Tibaldi, J. M. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.005 · Cited by 91
Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews
Martis, R., Brown, J., Alsweiler, J. M., Downie, M. R., & Crowther, C. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012327 · Cited by 86
Insulin Therapy in Children and Adolescents with Type 1 Diabetes
Malik, F. S., & Taplin, C. E. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0064-6 · Cited by 91
Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir
Peterson, G. E. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x154178 · Cited by 80
Insulin Glargine
McKeage, K., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161110-00007 · Cited by 78
Development of secreted proteins as biotherapeutic agents
Bonin-Debs, A. L., Boche, I., Gille, H., & Brinkmann, U. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.4.551 · Cited by 78
Insulin degludec: overview of a novel ultra long‐acting basal insulin
Gough, S. C. L., Harris, S. B., Woo, V. C., & Davies, M. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12052 · Cited by 74
New insulins in the treatment of diabetes mellitus
Lindholm, A. (2002) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2002.0321 · Cited by 73
Recent advances in treatment of youth with Type 1 diabetes: better care through technology
Tamborlane, W. V., Bonfig, W., & Boland, E. A. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00626.x · Cited by 70
Timely initiation of basal insulin
Riddle, M. C. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.003 · Cited by 71
Insulin analogues: an example of applied medical science
Sheldon, B., Russell‐Jones, D., & Wright, J. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01015.x · Cited by 69
Effects of Exercise on the Absorption of Insulin Glargine in Patients With Type 1 Diabetes
Peter, R., Luzio, S. D., Dunseath, G. J., Miles, A., Hare, B., Backx, K., Pauvaday, V., & Owens, D. R. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.560 · Cited by 66
Self-citation
Characterization and impact of peptide physicochemical properties on oral and subcutaneous delivery
Klepach, A., Tran, H., Mohammed, F. A., & ElSayed, M. E. H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114322 · Cited by 65
Survey of glargine use in 115 pregnant women with type 1 diabetes
Gallen, I. W., Jaap, A., Roland, J. M., & Chirayath, H. H. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02339.x · Cited by 60
Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials
Kramer, C. K., Retnakaran, R. R., & Zinman, B. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.014 · Cited by 63
Use of Insulin Glargine During Pregnancy in a Type 1 Diabetic Woman
Devlin, J. T., Hothersall, L., & Jl, W. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1095-a · Cited by 55
A Century of Progress in Diabetes Care with Insulin: A History of Innovations and Foundation for the Future
Lee, S., & Yoon, K. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0163 · Cited by 60
Intentional Overdose with Insulin Glargine and Insulin Aspart
Tofade, T. S., & Liles, E. A. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.14.1412.43147 · Cited by 52
pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity
Kohn, W. D., Micanovic, R., Myers, S. L., Vick, A., Kahl, S. D., Zhang, L., Strifler, B. A., Li, S., Shang, J., Beals, J. M., et al. (2007) · Peptides · doi:10.1016/j.peptides.2007.01.012 · Cited by 53
Insulin Glargine: a review 8 years after its introduction
Goykhman, S., Drincic, A., Desmangles, J., & Rendell, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902775677 · Cited by 49
Pharmacology of Insulin Detemir
Kurtzhals, P. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(07)80004-1 · Cited by 50
Early hypoglycaemia after accidental intramuscular injection of insulin glargine
Karges, B., Boehm, B. O., & Karges, W. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01654.x · Cited by 46
Use of Insulin Glargine During Pregnancy in Seven Type 1 Diabetic Women
Woolderink, J. M., van Loon, A. J., Storms, F., de Heide, L., & Hoogenberg, K. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2594 · Cited by 46
Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
Havelund, S., Ribel, U., Hubálek, F., Høeg-Jensen, T., Wahlund, P., & Jonassen, I. (2015) · Pharmaceutical Research · doi:10.1007/s11095-014-1614-x · Cited by 45
Insulins: Past, Present, and Future
Borgoño, C. A., & Zinman, B. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.002 · Cited by 48
Insulin glargine in the treatment of type 1 and type 2 diabetes
Barnett, A. H. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.1.59 · Cited by 42
Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs
Papa, G. F. S., Fedele, V., Chiavetta, A., Lorenti, I., Leotta, C., Luca, S., Rabuazzo, A. M., Piro, S., Alagona, C., Spadaro, L., et al. (2008) · Acta Diabetologica · doi:10.1007/s00592-007-0023-6 · Cited by 41
Use of Insulin Glargine During the First Weeks of Pregnancy in Five Type 1 Diabetic Women
Cianni, G. D., Volpe, L., Lencioni, C., Chatzianagnostou, K., Cuccuru, I., Ghio, A., Benzi, L., & Prato, S. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.982 · Cited by 41
Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus
Yki-J�rvinen, H. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.304 · Cited by 40
The endocrine pancreas and the control of blood glucose
Rang, H. P., Dale, M. M., Ritter, J., & Flower, R. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-06911-6.50031-1 · Cited by 38
Challenges in optimal metabolic control of diabetes
Liebl, A. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.286 · Cited by 37
Initiation of insulin glargine in children and adolescents with type 1 diabetes
Tan, C. Y., Wilson, D. M., & Buckingham, B. A. (2004) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2004.00039.x · Cited by 37
Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
Lepelley, P., Soenen, V., Preudhomme, C., Lai, J. L., Cosson, A., & Fenaux, P. (1994) · PubMed · Cited by 36
Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance
Owens, D. R. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1202916 · Cited by 36
Self-citation
Defining the Role of Insulin Detemir in Basal Insulin Therapy
Morales, J. (2007) · Drugs · doi:10.2165/00003495-200767170-00007 · Cited by 38
An overview of insulin glargine
Home, P., & Ashwell, S. G. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.317 · Cited by 35
Key indices of glycaemic variability for application in diabetes clinical practice
Monnier, L., Bonnet, F., Colette, C., Renard, É., & Owens, D. R. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101488 · Cited by 35
Self-citation
Management of pregestational diabetes mellitus: a comparison of guidelines
Tsakiridis, I. G., Mamopoulos, A. M., Athanasiadis, A. P., Kourtis, A., & Dagklis, T. (2020) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2020.1719481 · Cited by 36
Optimizing the Replacement of Basal Insulin in Type 1 Diabetes Mellitus: No Longer an Elusive Goal in the Post-NPH Era
Bolli, G. B., Andreoli, A. M., & Lucidi, P. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0039 · Cited by 33
Self-citation
Initiating and Intensifying Insulin Therapy in Type 2 Diabetes Mellitus
Tibaldi, J. M. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.023 · Cited by 32
Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation
Owens, D. R., Bailey, T. S., Fanelli, C. G., Yale, J., & Bolli, G. B. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.11.004 · Cited by 34
Self-citation
Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia-prone type 1 diabetes
Pickup, J. C., Kidd, J., Burmiston, S., & Yemane, N. (2005) · Practical Diabetes · doi:10.1002/pdi.732 · Cited by 31
Insulin treatment in diabetic pregnancy
Mathiesen, E. R., & Vaz, J. A. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.876 · Cited by 30
Verteporfin ocular photodynamic therapy
Bakri, S. J., & Kaiser, P. K. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.1.195 · Cited by 30
The Treat-to-Target Trial and Related Studies
Riddle, M. C. (2006) · Endocrine Practice · doi:10.4158/ep.12.s1.71 · Cited by 29
A Comprehensive Review of the Evolution of Insulin Development and Its Delivery Method
Sugumar, V., Ang, K. P., Al-Shanon, A. F., Sethi, G., Yong, P. V. C., Looi, C. Y., & Wong, W. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071406 · Cited by 29
INSULIN GLARGINE (LANTUS®)
Owens, & Griffiths, S. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11297.x · Cited by 38
New Developments in Insulin Therapy for Type 2 Diabetes
SORLI, C. H. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.006 · Cited by 31
Recent advances in the determination of insulins from biological fluids
Thomas, A., & Thevis, M. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.003 · Cited by 30
Insulin analogues and other developments in insulin therapy for diabetes
McAulay, V., & Frier, B. M. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.7.1141 · Cited by 28
Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes
Päivärinta, M., Tapanainen, P. J., & Veijola, R. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00341.x · Cited by 26
Polymer-Based Delivery of Peptide Drugs to Treat Diabetes: Normalizing Hyperglycemia and Preventing Diabetic Complications
Jeon, H., Lee, A.-J., & Ha, K. (2022) · BioChip Journal · doi:10.1007/s13206-022-00057-0 · Cited by 26
New Insulins and New Aspects in Insulin Delivery
Woo, V. C. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.04.006 · Cited by 25
The ongoing evolution of basal insulin therapy over 100 years and its promise for the future
Retnakaran, R. R., & Zinman, B. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14552 · Cited by 23
Degludec insulin: A novel basal insulin
Kalra, S., Unnikrishnan, A., Baruah, M. P., & Kalra, B. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.83056 · Cited by 23
Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE™ study
Yenigün, M., & Honka, M. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01973.x · Cited by 23
New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice
Bolli, G. B., & DeVries, J. H. (2015) · Diabetes Care · doi:10.2337/dc14-2314 · Cited by 22
Self-citation
Safety of insulin glargine
Berger, M. (2000) · The Lancet · doi:10.1016/s0140-6736(05)72989-5 · Cited by 22
Study of the Aggregation of Insulin Glargine by Light Scattering
Coppolino, R., Coppolino, S., & Villari, V. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20609 · Cited by 21
Insulin Analogues in Children and Teens with Type 1 Diabetes: Advantages and Caveats
Rachmiel, M., Perlman, K., & Daneman, D. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.07.010 · Cited by 20
A evolução da insulinoterapia no diabetes melito tipo 1
Pires, A. C., & Chacra, A. R. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000200014 · Cited by 21
A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
Candido, R., Wyne, K. L., & Romoli, E. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0422-4 · Cited by 22
Experience with Insulin Analogues in Children
Danne, T., Deiss, D., Hopfenmüller, W., von Schütz, W., & Kordonouri, O. (2002) · Hormone Research in Paediatrics · doi:10.1159/000053312 · Cited by 20
One-hundred year evolution of prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs
Bolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., & Owens, D. R. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154935 · Cited by 18
Self-citation
Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus
Chatterjee, S., Tringham, J. R., & Davies, M. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.10.1357 · Cited by 19
Current management of gestational diabetes mellitus
Menato, G., Bo, S., Signorile, A., Gallo, M., Cotrino, I., Poala, C. B., & Massobrio, M. (2007) · Expert Review of Obstetrics & Gynecology · doi:10.1586/17474108.3.1.73 · Cited by 19
Insulin analogues: have they changed insulin treatment and improved glycaemic control?
Madsbad, S. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.206 · Cited by 19
Insulin detemir: A historical perspective on a modern basal insulin analogue
Meneghini, L., Liebl, A., & Abrahamson, M. J. (2010) · Primary care diabetes · doi:10.1016/s1751-9918(10)60007-1 · Cited by 17
Analysis of oligomeric stability of insulin analogs using hydrogen/deuterium exchange mass spectrometry
Nakazawa, S., Hashii, N., Harazono, A., & Kawasaki, N. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.09.002 · Cited by 18
Glargine safety, diabetes and cancer
Rendell, M., Aktürk, H. K., & Tella, S. H. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.770469 · Cited by 18
Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management
Garber, A. J. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00457.x · Cited by 15
Modeling Subcutaneous Absorption of Long-Acting Insulin Glargine in Type 1 Diabetes
Schiavon, M., VISENTIN, R., Giegerich, C., Klabunde, T., Cobelli, C., & Man, C. D. (2019) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2019.2919250 · Cited by 15
The Association of Insulin Medication Possession Ratio, Use of Insulin Glargine, and Health Benefit Costs in Employees and Spouses With Type 2 Diabetes
Kleinman, N. L., Schaneman, J. L., & Lynch, W. D. (2008) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e3181875e9b · Cited by 15
Paediatric diabetes: achieving practical, effective insulin therapy in type 1 and type 2 diabetes
Danne, T., & BECKER, D. J. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00494.x · Cited by 15
A Brief Atlas of Insulin
Ayan, E. B., & DeMi̇rci̇, H. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666220610150342 · Cited by 14
Insights in Regulated Bioanalysis of Human Insulin and Insulin Analogs by Immunoanalytical Methods
Bowsher, R. R., & Nowatzke, W. L. (2011) · Bioanalysis · doi:10.4155/bio.11.50 · Cited by 14
Insulin Glargine Use During Pregnancy
Pantalone, K. M., Faiman, C., & Olansky, L. (2011) · Endocrine Practice · doi:10.4158/ep11083.ra · Cited by 13
Insulin glargine: a new basal insulin analogue
Younis, N. (2002) · QJM · doi:10.1093/qjmed/95.11.757 · Cited by 13
Insulin detemir, does a new century bring a better basal insulin?
Hordern, S. V. M., & Russell-Jones, D. L. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00544.x · Cited by 13

Authors: Bolli, G. B., & Owens, D. R.
Affiliations: University of Perugia (IT)
University of Wales (GB)
Corresponding author: Bolli, Geremia B
ORCID: Bolli, Geremia B
Owens, David R
Venue: The Lancet
Publisher: Elsevier BV
Published: 2000-08
Volume: 356
Issue: 9228
Pages: 443-445
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(00)02546-0
OpenAlex: W4243765000
Cited by: 186
References: 10
Citations by year: 2026: 7 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 8 · 2021: 8 · 2020: 1 · 2019: 4 · 2018: 10 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 3 · 2013: 8 · 2012: 6
FWCI: 8.07
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: insulin glargine, long-acting insulin analogues, basal insulin, type 1 diabetes, type 2 diabetes, drug approval, drug safety, insulin therapy
MeSH terms: Insulin Glargine, Blood Glucose, Diabetes Mellitus, Humans, Hypoglycemic Agents, Insulin, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Insulin glargine

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks